stockrowCG Oncology, Inc.
CGON Healthcare Biotechnology
CG Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, up 254.7% from fiscal 2024.
- Revenue
- −3.72%
- EPS
- −12.3%
- Free cash flow
- −25.2%
- Total debt
- 0.00%
Quarter to September 2026, against a year earlier
Follow CGON
Alert me
CG Oncology, Inc. (CGON) P/B ratio
As of 6 November 2026, CG Oncology, Inc. (CGON) trades at a P/B ratio of 6.8×. Over the past ten years it has ranged from 0.0× (March 2024) to 7.1× (March 2026); the current reading is higher than 99% of that period. That is above the Biotechnology industry median of 2.0× and above the Healthcare sector median of 2.3×.
P/B ratio, daily
Embed this chart
Annual newest first
| Period | P/B ratio | Change |
|---|---|---|
| FY2025 | 4.3× | 74.50% |
| FY2024 | 2.4× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
Quarterly newest first
| Period | P/B ratio | Change |
|---|---|---|
| Sep 2026 | 6.4× | 4.40% |
| Jun 2026 | 6.1× | 16.22% |
| Mar 2026 | 5.2× | 22.86% |
| Dec 2025 | 4.3× | (5.12%) |
| 9 more quarters | Free account |
Against its own ten years
P/B ratio against peers
| Company | P/B ratio |
|---|---|
| MIRM Mirum Pharmaceuticals, Inc. compare | n/m |
| PTCT PTC Therapeutics, Inc. compare | n/m |
| CGON CG Oncology, Inc. | 5.6× |
| LGND Ligand Pharmaceuticals Incorporated compare | 6.2× |
| MANE Veradermics Incorporated compare | 6.4× |
| BLTE Belite Bio, Inc. Sponsored ADR compare | 7.5× |
| IMVT Immunovant, Inc. compare | 8.0× |
| SRRK Scholar Rock Holding Corporation compare | 23.5× |
| KOD Kodiak Sciences Inc. compare | 94.0× |
| Biotechnology industry median | 2.0× |
| Healthcare sector median | 2.3× |
| Market median | 1.7× |
What P/B ratio is
Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.
Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))
More on CGON
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement